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Symposium: Risks of hypo-fractionation  
 
 
SP-0503   
Impact of geometrical uncertainties in stereotactic 
radiation therapy: risk assessment and clinical 
management 
A.M. Van Mourik1 
1Netherlands Cancer Institute Antoni van Leeuwenhoek 
Hospital, Radiotherapy Department, Amsterdam, The 
Netherlands  
 
In radiosurgery or stereotactic radiotherapy geometric 
inaccuracies are present throughout the treatment chain. 
Besides setup variability and intrafraction motion, geometric 
imperfections in treatment preparation, planning and dose 
delivery become relevant in stereotactic treatment. Their 
impact depends on the type of error (e.g. grand mean, 
systematic, random) and on technological treatment 
characteristics.  
Current perspectives on the management of these geometric 
uncertainties range between two extremes: the radiosurgery 
perspective (single fraction, ablative dose, no margins) and 
the radiotherapy perspective (hypo-fractionated, high dose, 
PTV/PRV margin). Various combinations of and adaptations 
on these perspectives are described in the literature. 
Additional considerations that influence the management of 
geometric uncertainties include: disease site, tumor type, 
treatment intent, treatment risk, radiobiology, clinical 
experience etc. In practice, the ways in which geometric 
uncertainties are accounted for vary per institute, per tumor 
(group) and even per patient; partly because of actual 
differences in geometric treatment characteristics and partly 
as a result of different views.  
Consistent management of geometric uncertainties within 
and across institutes is important for 1. establishing accurate 
dose-effect relations, 2. an unambiguous relationship 
between technology advancement and margin reduction or 
dose prescription for optimal treatment. Therefore, a unified 
perspective on geometric accuracy (with)in radiosurgery and 
stereotactic radiotherapy is warranted. By reviewing and 
comparing the different views, management and nature of 
geometric uncertainties in the chains of radiosurgery and 
stereotactic radiotherapy, we aim to contribute to such a 
unified perspective.  
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Impact of geometrical uncertainties in extreme hypo with 
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N. Nesvacil1, K. Tanderup2, R. Pötter1, C. Kirisits1 
1Medical University of Vienna, Department of Radiation 
Oncology Comprehensive Cancer Center, Vienna, Austria  
2Aarhus University Hospital, Department of Oncology 
Comprehensive Cancer Center, Aarhus, Denmark  
 
This presentation will include an overview of dosimetric 
uncertainties in interstitial/intracavitary brachytherapy and 
summarize the current state of our knowledge on the most 
dominant components for the total dosimetric uncertainties 
for specific types of BT.  
The impact of different systematic and random dosimetric 
uncertainties, caused by geometrical inter- and intra-fraction 
variations between BT applicator and organ positions, on the 
reported total dose (EQD2 for EBRT+HDR brachytherapy) 
depends on the fractionation schedule applied. Examples for 
the effect of reported uncertainties on different high dose 
rate fractionation schedules will include prostate and 
gynaecological BT. 
As the analysis of dose-response relationships depends on the 
reported total treatment doses, large systematic or random 
dosimetric uncertainties for BT will have a significant 
influence on the accuracy of outcome prediction. Based on 
recent literature, e.g. on inter-fraction variations during BT, 
and morbidity studies, the effect of uncertainties on the 
assessment of response probabilities for OARs can be 
estimated.  
Based on this discussion it might be possible to develop 
strategies for reducing uncertainties for dose planning and 
delivery in the future and therefore widen the therapeutic 
window.  
   
SP-0505   
Unexpected and under-estimated late toxicities with hypo-
fractionation 
J. Overgaard1 
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Abstract not received. 
   
SP-0506   
New radiobiology for severe/extreme hypo: abandoning 
the LQ model or integrating it ? 
M.C. Joiner1 
1Wayne State University, Radiation Oncology, Detroit, USA  
  
A massive amount of experimental work in the 1970’s and 
80’s on many models of normal-tissue injury in rodents and 
pigs, showed that “–ln(Surviving Fraction)” is best described 
by a second-order polynomial in dose, the well-known Linear-
Quadratic (LQ) equation. That LQ description has since been 
thoroughly tested in the clinical domain, but almost always in 
the “conventional” range of dose per fraction below 6 Gy. LQ 
is the simplest mathematical description of a non-linear 
relationship and though empirical in nature, it has 
nevertheless been subject to many attempts to connect with 
our understanding of how radiation injury is produced and 
repaired at the cell and molecular level. Yet any meaningful 
and clinically useful link in this respect has remained elusive. 
LQ deals specifically with the relationship between total dose 
and dose per fraction, and with interfraction interval using 
the Incomplete-Repair derivative model. The relationship 
between total dose and overall treatment time is an even 
more complex relationship dependent on the different 
underlying radiobiology of different tissues even within the 
apparently same category of early-reacting or late-reacting 
tissues, distinguished by respectively a “high” or “low” ratio 
of α/β in the LQ equation. Overall time is therefore better 
handled independently of LQ. 
A straightforward but untested hypothesis for the different 
α/β values for early- and late-reacting tissues, is that a 
naturally low α/β for a target cell population is smoothed out 
to a higher value as the sum of the responses of different 
proliferative subpopulations, and different phases of the cell 
cycle that these are in. This explanation could be applied to 
the responses of malignancies in the lung and head and neck, 
also adding in the additional response variation of cells at 
various levels of hypoxia in these sites. Of note is the 
connection between outcome of radiotherapy and HPV status 
in oropharyngeal cancers, which implies a possible difference 
in treatment strategy between these tumor subtypes and 
could also explain the high α/β of head and neck cancer 
overall as the sum of the responses of the different cancer 
subtypes (HPV + and -) which could both have low α/β but 
different radiosensitivity. In some malignancies, notably 
prostate and breast, clinical data do indeed indicate a low 
S248                                                                                                                                         3rd ESTRO Forum 2015 
 
α/β which might also reflect more uniformity in response 
perhaps more characteristic of lower proliferative or early-
stage disease. This has resulted in new efforts to test 
hypofractionation which have also been enabled by better 
dose localization achievable with image-guided Volumetric 
Modulated Arc Therapy. 
There is evidence that the LQ model becomes less reliable at 
doses per fraction < 1 Gy, due to possible low-dose hyper-
radiosensitivity, and also at > 6 Gy per fraction for reasons 
not yet understood though increasing vascular damage and 
immunological/inflammatory effects occur at higher doses 
per fraction. It is axiomatic that LQ must indeed 
overestimate effect at very high doses per fraction because 
the effective D0 would become unrealistically low. This 
makes the outcome of hypofractionated regimes less 
predictable: using LQ at high doses per fraction would be 
playing safe in predicting toxicity of hypofractionation, while 
overestimating the effect on the target malignancy, noting 
that possible hypoxia in a tumor could also limit the 
effectiveness of large dose fractions. 
    
 
Debate: Have we reached the technology edge in radiation 
therapy?  
 
 
SP-0507   
In radiotherapy, technology without radiobiology is like 
driving a Porsche at 40 kilometres per hourí 
A. Nahum1 
1The Clatterbridge Cancer Centre - Wirral NHS Foundation 
Trust, Physics Department, Bebington Wirral, United 
Kingdom  
 
Today’s external-beam radiotherapy (EBRT) is technologically 
sophisticated but radiobiologically primitive. Since the late 
1980s ‘Hi-tech’ has dominated EBRT at the expense of 
‘radiobiological intelligence’. Furthermore we have become 
slaves to the mantra  ‘evidence-based medicine’, with 
 evidence = phase-3 clinical trials: this ties our hands behind 
our backs. We prostrate ourselves before the ‘Collective 
Dose-Escalation Deity’ e.g. via advances such as MLCs, IMRT, 
even protons but largely reject individual dose-escalation 
based on (normal-tissue) patient DVHs   - this is illogical and 
does patients a disservice. We have become ‘hostages to 
commercial fortune’ – if the companies say ‘oh we cannot 
give you TCP or NTCP in our planning system in case someone 
sues us’ we meekly accept this!  This lamentable ‘worship of 
commercial interests’ is a negation of our dignity as scientists 
and our responsibility as medical practitioners. Today’s EBRT 
is ‘North Korean’ – instead it should be ‘South Korean’ i.e. 
based on enterprise and intelligence. Evolution equipped us 
with creative brains, which can do so much more than follow 
‘safety first’ protocols developed by committees. The ‘Hi-
tech’ gadgets of today are impressive but our use of them 
will remain largely pedestrian without the application of 
‘radiobiological intelligence’ – our patients expect no less.  
   
SP-0508   
Against the motion: No, new technological developments 
will always appear 
P. Munck af Rosenschöld1 
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The debate revolves around the impact of technology in 
radiotherapy (RT). RT as a field has a long tradition of high 
technology involvement, and practitioners are used to 
frequent technology advances. Recent technology advances 
include advanced imaging for planning and treatment 
verification, as well as rotational intensity modulation RT 
delivery. The ability to deliver the correct dose efficiently 
and with millimeter precision is now feasible at most modern 
RT departments. The question whether we have reached “the 
edge in radiotherapy” is therefore warranted. Even though 
the technology for planning and delivery has evolved, RT 
clinics rely much on manual procedures for tumor 
delineation, treatment planning, quality control test and 
treatment adaptation. Simultaneously, many RT clinics face 
the challenge of rising patient numbers to treat using the 
same equipment and with less staff. Further, most RT clinics 
lack systematic follow-up of treatment outcomes. I argue in 
this talk that new technology can improve RT cost-
effectiveness and patient outcomes. In addition, improved 
technology is warranted for safe personalized dose 
prescription and adapted radiation therapy. Technology 
advances can allow for automated procedures in the 
preparation of treatments, including delineation and planning 
Information technology solutions could automate the follow-
up procedures, including evaluation of quality of life, local 
control, patterns of relapse and survival.   
   
 
Symposium: MRI throughout the treatment chain  
 
 
SP-0509   
MR Imaging in Radiotherapy: The evolving role of the RTT 
G. Perkins1 
1Hamad Medical Corporation National Centre for Cancer Care 
& Research, Radiation Oncology, Doha, Qatar  
  
There is increasing interest and application of Magnetic 
Resonance Imaging simulation (MRI-SIM) into the radiotherapy 
localization and planning process. However, the knowledge 
base within the context of Radiation Therapy practice is still 
in development.  Further, workforce development and the 
training plans for RTTs working in this developing area of 
practice has been not yet been standardized. This session 
targeted at RTTs, aims to provide an overview of the issues 
involved in developing a service where MRI scans are acquired 
in the treatment position, for RT planning (MRI SIM). The 
session will review the basic principles of MR imaging, the 
rationale for its use in radiotherapy and typical pulse 
sequences and scan protocols used for radiotherapy 
localization (MR-SIM). The session will also provide 
an overview of MR scanner modifications and accessories 
utilized for MR-SIM. The typical clinical workflow for MR-SIM 
including patient preparation, safety issues, scan 
optimization and CT-MR image registration using clinical 
examples will be presented. An overview of common staffing 
models and training plans for RTT’s working in MR-SIM will be 
reviewed 
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